Roy S. Herbst, MD, PhD: Immunotherapy has an important role in all aspects of lung cancer, driver or nondriver disease. Certainly, in the patients with no known driver, immunotherapy offers hope that we haven’t seen in many years. We can use this drug in a certain percentage of frontline therapies that are PD-L1-positive—pretty much everyone is getting it now as a second-line therapy. It’s one of the drugs where we’re seeing activity: 20% or more response rates. Certainly, there are populations that benefit more. They’re the patients who are living disease-free for 5 to 6 years. We need to figure out what it is about those patients, and also what is it about those patients who receive immunotherapy for 6 weeks and are already progressing. That’s part of our research at places like Yale—we have a lung support grant that’s trying to figure that out.
There’s also a big role for immunotherapy in patients with driver mutations, because I’ve treated patients, for example, with EGFR inhibitors since the first clinical trials we did with gefitinib. We called it ZD1839 back then, in 1998, and no one was cured because patients became resistant to these targeted therapies. So, there has got to be a role for these immunotherapies in the patients who become resistant. It has been a bit challenging to incorporate them in, because of combined toxicities of small molecule EGFR inhibitors—especially the newest generation of drugs and these antibodies. But those trials are ongoing, and I think now that we understand how to better manage the toxicities. We will see that in place. There’s a role for immunotherapy across the whole spectrum of advanced non—small cell lung cancer.
PD-L1 expression is used in a number of ways. Certainly, if you’re going to use an agent that targets PD-1 or PD-L1 upfront in an untreated lung cancer patient, one would want to use a selected population that’s PD-L1-positive. That’s quite clear based on the KEYNOTE-024 trial showing that, in the patients that are PD-L1-positive at 50%, there’s a survival advantage: a hazard ratio 0.5; a PFS benefit 0.5; and a hazard ratio 0.6 for using pembrolizumab. Interestingly, with nivolumab using a cutoff much lower, that wasn’t seen. So, I think PD-L1 clearly has a role in choosing frontline treatment.
As far as using the drug in the second-line setting, given that PD-L1 is a dynamic marker and there’s some heterogeneity, it’s a little less clear. Certainly, in the KEYNOTE-010 trial on which I was the PI, we actually did see that, between the 1% and the 50% cutoffs, there was a clear improvement in the benefit of the pembrolizumab versus docetaxel.
You can use PD-L1 to tell you who’s more likely to benefit, but from the trials with nivolumab and atezolizumab—either one looked at the biomarker, with nivolumab, they looked at it more informally—there did appear to be benefit in the patients who were PD-L1-negative. I think that there are clearly patients who would benefit who are PD-L1-negative, either because it’s a false negative or because there are other mechanisms at play that we don’t understand yet, whether it be mutational load, neoantigen load, gene signatures—meaning what’s going on in the immune microenvironment— how many T cells there are, or what the character of T cells is. So, it’s still a bit of a moving target, but my feeling is that one can use these drugs in all settings.
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More